We are working On:

AbCellera’s unique business model brings our operating system to the industry through partnerships. Over the past six years, we have partnered on over 100 therapeutic antibody discovery programs, working with companies that span the gamut from early-stage biotech to some of the world’s largest and most enabled biopharmaceutical companies. By partnering with AbCellera, these groups can move more quickly, reduce costs, and tackle some of the toughest problems in antibody discovery. Typically, our partners come to us when they have identified the disease target. We then apply our technology to discover high quality potent antibodies that are suitable for development, and we return these antibodies to our partners for final preclinical development and clinical testing. This includes partnerships in oncology, inflammation, cardiovascular disease, pain, neurodegeneration and many more. We structure our agreements in a way that aligns our interests with the success of our partners and ultimately with the patients they serve. Our partnership agreements include technical access fees and research payments, clinical and commercial milestones and royalties on net sales of approved products.